Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
US Department of Justice
Fuji
Teva
UBS
Accenture
Deloitte
US Army
Daiichi Sankyo
McKesson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020520

« Back to Dashboard

NDA 020520 describes ZANTAC 75, which is a drug marketed by Sanofi Us and is included in two NDAs. It is available from five suppliers. Additional details are available on the ZANTAC 75 profile page.

The generic ingredient in ZANTAC 75 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. One hundred and forty-two suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
Summary for 020520
Tradename:ZANTAC 75
Applicant:Sanofi Us
Ingredient:ranitidine hydrochloride
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 020520
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0122 0597-0122-54 1 BOTTLE in 1 CARTON (0597-0122-54) > 60 TABLET, COATED in 1 BOTTLE
ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0122 0597-0122-08 1 TABLET, COATED in 1 POUCH (0597-0122-08)

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:TABLET;ORALStrengthEQ 75MG BASE
Approval Date:Dec 19, 1995TE:RLD:No

Expired US Patents for NDA 020520

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Us ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ➤ Subscribe ➤ Subscribe
Sanofi Us ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ➤ Subscribe ➤ Subscribe
Sanofi Us ZANTAC 75 ranitidine hydrochloride TABLET;ORAL 020520-001 Dec 19, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Accenture
Fish and Richardson
Cipla
US Department of Justice
Chubb
QuintilesIMS
Teva
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot